Partner Webinar: Hereditary Hemorrhagic Telangiectasia in 2021: Diagnosis and Advances in Treatment” 8/19/21 from 2:00-3:00 PM EDT

Cure HHT in conjunction with the CDC, through its Public Health Webinar Series, will be offering a free webinar on the topic of HHT, “Hereditary Hemorrhagic Telangiectasia in 2021: Diagnosis and Advances in Treatment” on Thursday, August 19, 2021, from 2:00-3:00 PM EDT.    Dr. Kasthuri and Dr. Al-Samkari, Directors of the HHT Centers of Excellence at UNC and MGH respectively, will discuss various aspects of HHT including inheritance, clinical manifestations, approach to diagnosis, screening and management.   The prevalence of anemia in the HHT population and challenges with its management that are unique to HHT will be emphasized, as will the emergence of systemic therapies to treat bleeding. In particular, systemic antiangiogenic treatments that are changing the treatment landscape of HHT will be highlighted.   Additionally, the recently published Second International Guidelines for the Diagnosis and Treatment of HHT will be reviewed and discussed.   Faculty:  Raj Kasthuri, MBBS, MD; Professor of Medicine, Division of Hematology; Director of the UNC Hereditary Hemorrhagic Telangiectasia Center of Excellence; Associate Director for Clinical Research, UNC Blood Research Center; University of North Carolina at Chapel Hill   Hanny Al-Samkari, MD; Assistant Professor of Medicine, Harvard Medical School; Classical Hematologist and Clinical Investigator, Division of Hematology Oncology, Massachusetts General Hospital; Associate Director of the Massachusetts General Hospital Hereditary Hemorrhagic Telangiectasia Center of Excellence   Learning Objectives:

• List common presentations and an approach to the diagnosis of HHT
• Describe some of the challenges with anemia management in HHT and strategies that may be helpful in its management
• Describe the HHT Treatment Guidelines and recognize the emergence of systemic antiangiogenic therapies as a treatment modality in HHT

---